欢迎进入UG环球官网(环球UG)!

choi baccarat(www.vng.app):Exclusive: AstraZeneca to seek U.S. authorization for COVID-19 vaccine this month or early next - sources

admin1个月前18

USDT官网

菜宝钱包(caibao.it)是使用TRC-20协议的Usdt第三方支付平台,Usdt收款平台、Usdt自动充提平台、usdt跑分平台。免费提供入金通道、Usdt钱包支付接口、Usdt自动充值接口、Usdt无需实名寄售回收。菜宝Usdt钱包一键生成Usdt钱包、一键调用API接口、一键无实名出售Usdt。

choi Baccarat

sàn casino đổi thưởng tiền mặt uy tín SỐ 1 ,Bạn có thể nạp và rút tiền với; Ví điện tử ; đồng tiền ảo; usdt; an toàn tiện lợi và có độ bảo mật cao. Mọi thông tin chi tiết xin liên hệ URL:www.vng.app。

,CHICAGO - AstraZeneca Plc is preparing to file for U.S. emergency use authorization (EUA) for its COVID-19 vaccine later this month or early April after accumulating enough data to judge the inoculation's efficacy, sources with knowledge of the ongoing clinical trial told Reuters on Friday. The British drugmaker completed enrollment in its trial of more than 32,000 volunteers in January and now has data on at least 150 cases of COVID-19, two sources familiar with the trial told Reuters. The number of COVID-19 cases among those who got the vaccine versus infections in participants who received a placebo will show how effective the AstraZeneca shot was at preventing illness in those age 18 and over. The AstraZeneca vaccine, developed in collaboration with Oxford University, has been authorized for use in theEuropean Union and many countries but not yet by U.S. regulators. "The U.S. Phase III study results are necessary for the FDA’s evaluation of an EUA request for our vaccine," a company spokeswoman said, without confirming trial details being reported by Reuters. "We expect data from our U.S. Phase III trial to be available soon, in the coming weeks, and we plan to file for emergency use authorization shortly thereafter." Highly anticipated results from the U.S. trial could help settle safety concerns arising over reports of serious blood clots in some vaccine recipients that have led several nations to pause administering the vaccine. A World Health Organization expert advisory committee islooking into the matter. The data could also help determine what becomes of doses already sitting in U.S. warehouses awaiting approval. The New York Times reported on Thursday that some countries have been asking to procure doses of the vaccine not currently being offered in the United States. AstraZeneca said in February it expects its vaccine could receive U.S. emergency use authorization at the beginning of April and could immediately deliver 30 million doses to locations around the United States. In a Friday press briefing, White House Coronavirus Response Coordinator Jeff Zients said the United States has a small inventory of the AstraZeneca vaccine, which it plans to keep and deploy to Americans should an EUA be granted. The U.S. stance could thwart AstraZeneca’s efforts to come closer to delivering on its contractual obligation with the EU of 180 million doses in the second quarter. AstraZeneca told the EU earlier this year it would cut its supplies in the second quarter by at least half to less than 90 million doses, EU sources told Reuters, after a bigger reduction in the first three months of the year. REUTERS
转载说明:本文转载自Sunbet。
上一篇 下一篇

猜你喜欢

网友评论

随机文章
热门文章
热评文章
热门标签